GTBP · Company research
GT Biopharma Inc. Common Stock (GTBP): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. - Stock Titan | With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Regains Nasdaq Minimum Bid Compliance - The Globe and Mail | GT Biopharma Regains Nasdaq Minimum Bid Compliance The Globe and Mail | View source ↗ | The Globe and Mail | Sep 26, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Expands Series M Preferred Financing Agreement - The Globe and Mail | GT Biopharma Expands Series M Preferred Financing Agreement The Globe and Mail | View source ↗ | The Globe and Mail | Sep 22, 2026 | neutral | 0 | 0.6 |
| GT Biopharma (GTBP) Slides 4.41% to $7.16 as Shares Test Key Support Zone - Bollinger Squeeze - www.dars.gov.et | GT Biopharma (GTBP) Slides 4.41% to $7.16 as Shares Test Key Support Zone - Bollinger Squeeze www.dars.gov.et | View source ↗ | www.dars.gov.et | Sep 21, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Inc. (GTBP) Key Financial Ratios – Valuation, Profitability & More - Value Research | GT Biopharma Inc. (GTBP) Key Financial Ratios – Valuation, Profitability & More Value Research | View source ↗ | Value Research | Aug 27, 2026 | neutral | 0 | 0.6 |
| GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan | GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Inc (NASDAQ: GTBP) Share Price, GTBP Stock News, GTBP Share Price & Updates - Kalkine | GT Biopharma Inc (NASDAQ: GTBP) Share Price, GTBP Stock News, GTBP Share Price & Updates Kalkine | View source ↗ | Kalkine | Aug 13, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Inc (GTBP) Stock News Today - TradingKey | GT Biopharma Inc (GTBP) Stock News Today TradingKey | View source ↗ | TradingKey | Aug 7, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Inc (GTBP) Earnings Date & Reports & Earnings News - TradingKey | GT Biopharma Inc (GTBP) Earnings Date & Reports & Earnings News TradingKey | View source ↗ | TradingKey | Jul 26, 2026 | neutral | 0 | 0.6 |
| GT Biopharma (GTBP) Slides to $0.42 Amid Continued Selling Pressure - Last Point Resistance - po-news-eg.net | GT Biopharma (GTBP) Slides to $0.42 Amid Continued Selling Pressure - Last Point Resistance po-news-eg.net | View source ↗ | po-news-eg.net | Jul 10, 2026 | neutral | 0 | 0.6 |
| GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance | GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Mar 16, 2026 | neutral | 0 | 0.6 |
| GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance | GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Yahoo Finance | View source ↗ | Yahoo Finance | Mar 12, 2026 | neutral | 0 | 0.6 |
| What date does GT Biopharma's (GTBP) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research | What date does GT Biopharma's (GTBP) report Earnings - Earnings Calendar & Announcement Zacks Investment Research | View source ↗ | Zacks Investment Research | Mar 12, 2026 | neutral | 0 | 0.6 |
| Should I buy GT Biopharma (GTBP) - Zacks Investment Research | Should I buy GT Biopharma (GTBP) Zacks Investment Research | View source ↗ | Zacks Investment Research | Mar 12, 2026 | neutral | 0 | 0.6 |
| GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3 - Quiver Quantitative | GT Biopharma Announces FDA Clearance for GTB-5550 Phase 1 Clinical Trial Targeting Solid Tumors Expressing B7-H3 Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 3, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 26, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.